• Purity

  >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

• Endotoxin Level

  <0.01 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by its ability to induce IL-8 secretion by HepG2 human hepatocellular carcinoma cells. Tang, Y.     et al. (2011) Clin. Exp. Immunol.     166:281. The ED    ₅₀ for this effect is 0.4-2 μg/mL.

• Source

  E. coli-derived His21-Phe180, with an N-terminal Met

• Accession #

• N-terminal Sequence    
  Analysis

  Met

• Predicted Molecular Mass

  18.2 kDa (monomer)

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Background: IL-17B

Interleukin-17B (IL-17B), is an approximately 20 kDa glycosylated cytokine that plays a role in inflammation and bone growth. The six IL-17 cytokines (IL-17A-F) are encoded by separate genes but adopt a conserved cystine knot fold (1, 2). Mature mouse IL-17B shares 90% and 98% amino acid sequence identity with human and rat IL-17B, respectively (3). IL-17B binds to IL-17 RB and induces the production of inflammatory cytokines and the infiltration of inflammatory immune cells (3, 4). IL-17B is expressed in the central nervous system, testis, ovary, stomach, pancreas, and small intestine (3-5). In the skeletal system, IL-17B is expressed in bone collars surrounding primary ossification centers as well as in epiphyseal plate chondrocytes during development and after bone fracture (6, 7). IL-17B is up-regulated in arthritic cartilage where it exacerbates the severity of disease (8). It is also up-regulated in aggressive breast cancer cell lines, and its exaggerated signaling through IL-17RB promotes tumorigenicity (9). It inhibits the adhesion of vascular endothelial cells to Matrigel and enhances their migration (10)

• References:

1. Gaffen, S.L. (2009) Nat. Rev. Immunol. 9:556.

2. Cua, D.J. and C.M. Tato (2010) Nat. Rev. Immunol. 10:479.

3. Shi, Y. et al. (2000) J. Biol. Chem. 275:19167.

4. Li, H. et al. (2000) Proc. Natl. Acad. Sci. USA 97:773.

5. Moore, E.E. et al. (2002) Neuromuscul. Disord. 12:141.

6. Kokubu, T. et al. (2008) J. Histochem. Cytochem. 56:89.

7. You, Z. et al. (2005) Biochem. Biophys. Res. Commun. 326:624.

8. Yamaguchi, Y. et al. (2007) J. Immunol. 179:7128.

9. Huang, C.-K. et al. (2013) Oncogene July 15 Epub.

10. Sanders, A.J. et al. (2010) J. Oncol. 2010:817375.

• Long Name:

  Interleukin 17B

• Entrez Gene IDs:

  27190 (Human); 56069 (Mouse)

• Alternate Names:

  Cytokine Zcyto7; cytokine-like protein ZCYTO7; IL17B; IL-17B; IL-17Binterleukin-17 beta; IL20; IL-20interleukin-17B; interleukin 17B; interleukin 20; Interleukin-20; MGC138900; MGC138901; neuronal interleukin-17 related factor; Neuronal interleukin-17-related factor; NIRF; ZCYTO7interleukin-20